UK: NICE published draft guidance in which enzalutamide is not recommended as a drug to treat advanced prostate cancer. It says enzalutamide. also called Xtandi, manufactured by Astellas Pharma) is not a cost effective, pre chemotherapy treatment with too many uncertainties associated with evidence provided by manufacturer. …more
Categories
Archives
Our Projects
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy
To find out more, including how to control cookies, see here: Cookie Policy